Janumet 50mg/500mg Tablet is a combination oral antihyperglycemic agent containing Sitagliptin 50mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active incretin hormones, thereby improving glucose-dependent insulin secretion and decreasing glucagon release. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. Janumet is prescribed as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on metformin alone or in combination with other antidiabetic agents. The dual mechanism of action targets multiple pathophysiological defects in type 2 diabetes, offering complementary effects on fasting and postprandial blood glucose levels. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, with rare but serious risks including lactic acidosis associated with metformin. Janumet should be used cautiously in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. Regular monitoring of renal function and glycemic parameters is recommended during therapy. This combination therapy provides an effective option for optimizing glycemic control in type 2 diabetes management.